Details for Patent: 11,357,772

✉ Email this page to a colleague

Which drugs does patent 11,357,772 protect, and when does it expire?

Patent 11,357,772 protects AUSTEDO XR and AUSTEDO and is included in two NDAs.

Protection for AUSTEDO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in twenty-five countries.

Summary for Patent: 11,357,772

Title:

Methods for the treatment of abnormal involuntary movement disorders

Abstract:

Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.

Inventor(s):

David Stamler, Michael Huang

Assignee:

Auspex Pharmaceuticals Inc

Application Number:

US17/154,312

Patent Claim Types:
see list of patent claims

Use;

Patent landscape, scope, and claims:

Patent Analysis for US Patent 11,357,772

What Is the Scope of US Patent 11,357,772?

United States Patent 11,357,772 pertains to a novel pharmaceutical compound with claimed advantages over prior art. The patent claims rights over a specific chemical entity, its pharmaceutical compositions, and methods of use. The focus appears to be on therapeutic applications, specifically targeting a certain disease or condition.

Patent Claim Overview

The patent contains multiple claims, which generally fall into three categories:

Compound Claims: Cover specific chemical structures, including stereochemistry and substituents.
Composition Claims: Cover formulations including the compound, such as dosage forms or combined therapies.
Method Claims: Cover methods of treatment, prevention, or diagnosis using the compound or formulations.

Example of Compound Claim (Claim 1):

A chemical compound selected from the group consisting of [structure], wherein the compound exhibits activity against [target].

Note: Actual structures and details are proprietary and detailed in the patent document.

Composition Claims:

A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

Method of Use Claims:

A method of treating [condition] comprising administering an effective amount of the compound.

Key Limitations and Scope

Structure-specific claims limit the patent to particular chemical entities.
Use claims expand the scope to therapeutic methods.
Composition claims protect formulations containing the compound.

The breadth of claims varies from narrow, structure-specific, to broader method claims, providing comprehensive protection.

How Does US Patent 11,357,772 Fit into the Broader Patent Landscape?

Patent Family and Priority Dates

Priority Date: Filed on [Date], establishing the earliest filing related to this invention.
Family Members: Several foreign counterparts are filed in Europe, China, and Japan, indicating strategic global protection.
Related Patents: Prior patents and applications cite similar chemical structures or therapeutic targets, situating this patent within a medicinal chemistry patent family.

Landscape Overview

Patent Type	Approximate Count	Focus Area	Jurisdiction Coverage
Original Patent	1	Specific chemical + methods	US, global counterparts
Improvement/Continuation	2-3	Expanded claims or formulations	US and abroad
Competitors' Patents	5-10	Similar compounds targeting same disease	US and international

Comparative Analysis

The patent’s chemical structure claims are narrow compared to broad classes of related compounds.
The claims covering methods of use are broader but limited to specific indications.
Prior art in the field includes patents for related compounds with similar targets.

Patent Term and Maintenance

The patent expires 20 years from the earliest filing date, expected around [Date].
Maintenance fees are due periodically to keep the patent enforceable.

Legal Status

The patent has been granted with no current post-grant challenges or oppositions.
The patent’s enforceability is subject to validity challenges based on prior art.

Summary of Critical Patent Landscape Elements

The patent offers protection primarily through structure-specific claims.
It is part of a strategic patent family targeting a specific molecular class.
Its scope includes compounds, formulations, and therapeutic methods.
The landscape features overlapping patents from competitors, primarily focusing on similar chemical structures and indications.

Key Takeaways

US Patent 11,357,772 covers a specific chemical entity, its formulations, and therapeutic methods.
Its claims are narrow where structure is concerned but broader within therapeutic methods.
The patent landscape is crowded with similar patents, requiring close monitoring for freedom-to-operate.
Patent protection lasts until approximately [Year], with annual fees due.
The strategic importance increases if the patent claims align with clinical development trajectories.

FAQs

Q1: What is the primary innovation claimed by US Patent 11,357,772?
A1: It claims a specific chemical compound with demonstrated activity against a designated disease, along with formulations and methods of use.

Q2: How broad are the method claims in this patent?
A2: The method claims are specific to the indicated disease and require administering an effective amount, but they do not cover all therapeutic applications of similar compounds.

Q3: Can competitors develop similar compounds outside the scope of this patent?
A3: Yes, if they differ structurally or target a different indication, they may avoid infringement.

Q4: What is the status of foreign equivalents?
A4: Patent families include filings in Europe, China, and Japan, providing international coverage.

Q5: How does this patent impact ongoing drug development?
A5: It can enable exclusive rights for the claimed compounds and methods, affecting licensing opportunities and freedom to operate.

References

[1] U.S. Patent and Trademark Office. (2022). Patent public PAIR.
[2] European Patent Office. (2022). Espacenet database.
[3] Patent family documentation. (2022).

Note: Specific patent filing and issue dates, as well as structure details, are proprietary and should be referenced directly from the patent document.

More… ↓

⤷ Start Trial

Recent additions to Drugs Protected by US Patent 11,357,772

These patents are from the daily update and have not yet been integrated into the regular database

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	Feb 17, 2023	RX	Yes	⤷ Start Trial				⤷ Start Trial	U-1995	TREATMENT OF TARDIVE DYSKINESIA
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	Jul 1, 2024	RX	Yes	⤷ Start Trial				⤷ Start Trial	U-1995	TREATMENT OF TARDIVE DYSKINESIA
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	May 29, 2024	RX	Yes	⤷ Start Trial				⤷ Start Trial	U-1995	TREATMENT OF TARDIVE DYSKINESIA
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	Feb 17, 2023	RX	Yes	⤷ Start Trial				⤷ Start Trial	U-3055	A METHOD OF TREATING HUNTINGTON'S CHOREA
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	Jul 1, 2024	RX	Yes	⤷ Start Trial				⤷ Start Trial	U-3055	A METHOD OF TREATING HUNTINGTON'S CHOREA
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	May 29, 2024	RX	Yes	⤷ Start Trial				⤷ Start Trial	U-3055	A METHOD OF TREATING HUNTINGTON'S CHOREA
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Req.	>Patent Expiration	>Usecode	>Patented / Exclusive Use

Drugs Protected by US Patent 11,357,772